OKYO Pharma's OK-101 Phase 2 Trial shows rapid enrollment for dry eye disease treatment. Top-line data expected by 2023. Addressing significant unmet need in the market.
Discover the potential of gene therapy for treating AMD. UC Davis Health's successful trial shows promise in reducing injections and maintaining vision.
Discover a groundbreaking stem cell breakthrough that has partially restored vision for workers with severe eye injuries. This innovative procedure offers hope to those faced with permanent blindness.
FDA approves Xdemvy for Demodex blepharitis treatment. Find out how this targeted solution addresses the root cause of the condition, providing new hope for sufferers.
ABVC BioPharma implements 1-for-10 reverse stock split to regain Nasdaq compliance and attract investors in the ophthalmology, neurology, and oncology/hematology sectors.
Discover a groundbreaking stem cell breakthrough that has partially restored vision for workers with severe eye injuries. This innovative procedure offers hope to those faced with permanent blindness.
OKYO Pharma's OK-101 Phase 2 Trial shows rapid enrollment for dry eye disease treatment. Top-line data expected by 2023. Addressing significant unmet need in the market.